|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12Q 1/68 | (2018.01) |
| C12Q 1/6886 | (2013.01) | ||
| C12Q2600/106 | (2013.01) | ||
| C12Q2600/156 | (2013.01) | ||
| A61P 15/00 | (2018.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61P 43/00 | (2018.01) |
| (11) | Number of the document | 3350346 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16775507.3 |
| Date of filing the European patent application | 2016-09-16 | |
| (97) | Date of publication of the European application | 2018-07-25 |
| (45) | Date of publication and mention of the grant of the patent | 2023-01-04 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2016/072069 |
| Date | 2016-09-16 |
| (87) | Number | WO 2017/046394 |
| Date | 2017-03-23 |
| (30) | Number | Date | Country code |
| 201562219698 P | 2015-09-17 | US |
| (72) |
VALDERAS, Alvaro, Avivar , GB
CRUZALEGUI, Francisco, Humberto , GB
HUDSON, Kevin , GB
MCEWEN, Robert, Kenneth , GB
|
| (73) |
Astrazeneca AB ,
151 85 Södertälje,
SE
|
| (54) | NOVEL BIOMARKERS AND METHODS OF TREATING CANCER |
| NOVEL BIOMARKERS AND METHODS OF TREATING CANCER |